Replies to post #64 on Provention Bio, Inc. (PRVB)

[adamp]

they have over 100M in cash and securities. i don't think any of that matters. What matters is that they're charging $200k for a treatment that doesn't even offer a cure, only a very short term delay of disease progression. I'm surprised the FDA even approved it, but i bought back in when they did, assuming they truly believed in this drug. Only PRVB can struggle to close even on a day they get a major drug approved. Every other pharma doubles or triples on this news